The objective of this study is to determine the association between hypertensive disorders (HTNP) including chronic hypertension, gestational hypertension, pre-eclampsia with and without severe features, and HELLP syndrome and incidence of neonatal chronic lung disease.

15-hydroxyprostaglandin dehydrogenase (HPGD) is an enzyme that oxidizes prostaglandins(PGs), including key parturition mediators PGE2 and PGF2α.

Dyslipidemia is a disorder of the lipoproteins which promotes development of atherosclerosis. Overtime, atherosclerosis can lead to cardiovascular disease. Cardiovascular disease is the leading cause of maternal death in the United States.

Pregnancy is associated with atherogenic changes in lipid metabolism. Obesity is increasing in prevalence and closely associated with dyslipidemia characterized by high TC, LDL-C, and/or triglycerides, or low HDL-C.

Anemia is associated with adverse maternal and neonatal outcomes. In 2021, the American College of Obstetricians and Gynecologists (ACOG) eliminated race-based definitions of anemia from screening recommendations. We aimed to assess how a non-race-based anemia protocol reduces disparities between patients receiving care at two different prenatal sites.

Introduction of transmembrane conductance regulator modulator therapy in 2012 revolutionized the treatment of cystic fibrosis (CF). These therapies are now used in pregnancy.

Rate-Pressure Product (RPP) has been utilized in non-pregnant adults as a surrogate for myocardial oxygen consumption (MOC), a dynamic non-invasive index of changes in cardiovascular (CV) demand. We sought to describe pre-conceptional (PC), antepartum(AP), and postpartum (PP) RPP among low-risk pregnancies.

Rate-Pressure Product (RPP) has been used as a surrogate for myocardial oxygen consumption (MOC), a dynamic non-invasive index of changes in cardiovascular (CV)demand. We sought to describe pre-conceptional (PC), antepartum (AP), and postpartum (PP) RPP among pregnancies complicated by hypertensive disorders of pregnancy (HDP).

Rate-Pressure Product (RPP) has been used in non-pregnant adults as a surrogate for myocardial oxygen consumption (MOC), a dynamic non-invasive index of changes in cardiovascular (CV) demand. We sought to compare pre-conceptional (PC), antepartum(AP), and postpartum (PP) changes in MOC between low-risk pregnancies and those complicated by hypertensive disorders of pregnancy (HDP).